Investor Biogen Inc.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Biogen Inc. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-07-30 13D/A SAGE / Sage Therapeutics, Inc. 6,241,473 0
2025-07-21 13D/A SAGE / Sage Therapeutics, Inc. 6,241,473 6,241,473
2025-01-10 13D SAGE / Sage Therapeutics, Inc. 6,241,473 6,241,473
2024-11-07 13G/A DNLI / Denali Therapeutics Inc. 12,751,365 7,155,243
2024-08-16 13G/A SGMO / Sangamo Therapeutics, Inc. 14,652,466 3,250,000
2024-02-12 13G/A SGMO / Sangamo Therapeutics, Inc. 24,420,157 14,652,466
2024-02-12 13G/A DNLI / Denali Therapeutics Inc. 13,310,243 12,751,365
2023-09-28 13D/A RETA / Reata Pharmaceuticals Inc - Class A 8,936,791 0
2023-08-07 13D RETA / Reata Pharmaceuticals Inc - Class A 8,936,791
2021-01-11 13G SAGE / Sage Therapeutics, Inc. 6,241,473
2020-09-28 13G DNLI / Denali Therapeutics Inc. 13,310,243
2020-04-17 13G SGMO / Sangamo Therapeutics, Inc. 24,420,157
2020-02-11 13G/A AGTC / Applied Genetic Technologies Corp 1,453,957 0
2020-02-11 13G/A IONS / Ionis Pharmaceuticals, Inc. 11,501,153
2019-03-14 13D NITE / Capitol Series Trust - The Nightview Fund 20,638,209
2019-02-14 13G SLDB / Solid Biosciences Inc. 1,772,464
2018-06-07 13G IONS / Ionis Pharmaceuticals, Inc. 11,501,153
2015-08-20 13G AGTC / Applied Genetic Technologies Corp 1,453,957
2012-02-13 13G/A AVEO / AVEO Pharmaceuticals Inc 0
2012-02-13 13G/A VIRX / Viracta Therapeutics, Inc. 0